Ashwin Jaikishen, MD
Nephrology · Metairie, LANPI 1437449923
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (54.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Fresenius USA Marketing, Inc. accounts for 73.0% of it on its own, with 19 other manufacturers making up the rest. 2025 is the largest year on record at $14,941, more than ten times the $627 reported in 2019. Among nephrology clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 206 payments — averaging $95.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius USA Marketing, Inc.$14K
- Calliditas Therapeutics US Inc.$2K
- Amgen$771
- Mallinckrodt Hospital Products Inc.$387
- AstraZeneca$387
- Bayer$334
- plus $1K from 14 others
What the payments were for
- Consulting fees$4,20021%
- Travel & lodging$10,77455%
- Food & beverage$4,41122%
- Education$3082%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius USA Marketing, Inc. | 17 | $14,367 |
| Calliditas Therapeutics US Inc. | 7 | $2,088 |
| Amgen(2 entities) | 60 | $771 |
| Mallinckrodt Hospital Products Inc. | 12 | $387 |
| AstraZeneca(2 entities) | 20 | $387 |
| Bayer | 17 | $334 |
| Akebia Therapeutics Inc | 16 | $262 |
| Vifor Pharma, Inc. | 12 | $184 |
| Aurinia Pharma U.S., Inc. | 4 | $171 |
| Novo Nordisk | 4 | $161 |
| Otsuka America Pharmaceutical, Inc. | 8 | $141 |
| OPKO Pharmaceuticals, LLC | 8 | $137 |
| Travere Therapeutics, Inc. | 10 | $93 |
| Boehringer Ingelheim | 3 | $63 |
| Nxstage Medical, Inc. | 1 | $34 |
| Mallinckrodt Enterprises LLC | 2 | $32 |
| Lilly USA, LLC | 2 | $29 |
| Ardelyx, Inc. | 1 | $26 |
| Cormedix Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,693 in reported general payments places this provider in the 90th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 210 | $187,960 |
| JardianceEmpagliflozin | 138 | $168,059 |
| KerendiaFinerenone | 108 | $112,644 |
| VeltassaPatiromer Calcium Sorbitex | 25 | $59,709 |
| VelphoroSucroferric Oxyhydroxide | 13 | $46,677 |
| AuryxiaFerric Citrate | 11 | $31,207 |
| LokelmaSodium Zirconium Cyclosilicate | 11 | $18,995 |
| EliquisApixaban | 11 | $17,750 |
| Sevelamer Carbonate | 72 | $12,258 |
| Lanthanum Carbonate | 14 | $12,211 |
| DapagliflozinDapagliflozin Propanediol | 15 | $7,383 |
| Bumetanide | 120 | $6,055 |
| Potassium Citrate ErPotassium Citrate | 66 | $5,528 |
| TradjentaLinagliptin | 11 | $5,429 |
| Nebivolol Hcl | 52 | $2,512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $387 | $206,955221 claims |
| Boehringer IngelheimJardiance, Tradjenta | $63 | $173,488149 claims |
| BayerKerendia | $334 | $112,644108 claims |
| Fresenius USA Marketing, Inc.Velphoro | $14,367 | $46,67713 claims |
| Akebia Therapeutics IncAuryxia | $262 | $31,20711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 206 nephrology providers in Louisiana.
Other nephrology in Metairie
- Jill LindbergMetairie$28K
- Oksana NimkevychMetairie$18K
- Sreedhara AllaShreveport$722K
- Anthony BlalockLafayette$350K
- Juan Carlos VelezNew Orleans$282K
- Jones SamuelBaton Rouge$207K
- Jon MaresCovington$103K
- Raja ZabanehShreveport$57K
- Michael TouchyNew Orleans$56K
- Kenneth AbreoShreveport$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.